These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 22066985)
1. Cost-effectiveness of prasugrel in a US managed care population. Mauskopf JA; Graham JB; Bae JP; Ramaswamy K; Zagar AJ; Magnuson EA; Cohen DJ; Meadows ES J Med Econ; 2012; 15(1):166-74. PubMed ID: 22066985 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Mahoney EM; Wang K; Arnold SV; Proskorovsky I; Wiviott S; Antman E; Braunwald E; Cohen DJ Circulation; 2010 Jan; 121(1):71-9. PubMed ID: 20026770 [TBL] [Abstract][Full Text] [Related]
3. Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey. Davies A; Bakhai A; Schmitt C; Barrett A; Graham-Clarke P; Sculpher M J Med Econ; 2013; 16(4):510-21. PubMed ID: 23339464 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome. Coleman CI; Limone BL Am J Cardiol; 2013 Aug; 112(3):355-62. PubMed ID: 23631863 [TBL] [Abstract][Full Text] [Related]
5. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden. Lindgren P; Stenestrand U; Malmberg K; Jönsson B Clin Ther; 2005 Jan; 27(1):100-10. PubMed ID: 15763611 [TBL] [Abstract][Full Text] [Related]
6. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy. Pride YB; Wiviott SD; Buros JL; Zorkun C; Tariq MU; Antman EM; Braunwald E; Gibson CM; Am Heart J; 2009 Sep; 158(3):e21-6. PubMed ID: 19699846 [TBL] [Abstract][Full Text] [Related]
7. Prasugrel compared to clopidogrel in patients with acute coronary syndrome undergoing percutenaous coronary intervention: a Spanish model-based cost effectiveness analysis. Davies A; Sculpher M; Barrett A; Huete T; Sacristán JA; Dilla T Farm Hosp; 2013; 37(4):307-16. PubMed ID: 24010692 [TBL] [Abstract][Full Text] [Related]
8. Prasugrel: a guide to its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention in the US. Lyseng-Williamson KA Am J Cardiovasc Drugs; 2012 Jun; 12(3):207-16. PubMed ID: 22583148 [TBL] [Abstract][Full Text] [Related]
9. Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention. Greenhalgh J; Bagust A; Boland A; Saborido CM; Fleeman N; McLeod C; Dundar Y; Dickson R; Proudlove C; Kolamunnage-Dona R; Fisher M Health Technol Assess; 2010 May; 14 Suppl 1():31-8. PubMed ID: 20507801 [TBL] [Abstract][Full Text] [Related]
10. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes. Toth PP Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814 [TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis. Kourlaba G; Fragoulakis V; Maniadakis N Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992 [TBL] [Abstract][Full Text] [Related]
12. The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation. Panattoni L; Brown PM; Te Ao B; Webster M; Gladding P Pharmacoeconomics; 2012 Nov; 30(11):1067-84. PubMed ID: 22974536 [TBL] [Abstract][Full Text] [Related]
13. Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. Mahoney EM; Mehta S; Yuan Y; Jackson J; Chen R; Gabriel S; Lamy A; Culler S; Caro J; Yusuf S; Weintraub WS; Am Heart J; 2006 Jan; 151(1):219-27. PubMed ID: 16368322 [TBL] [Abstract][Full Text] [Related]
14. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E; Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. Kazi DS; Garber AM; Shah RU; Dudley RA; Mell MW; Rhee C; Moshkevich S; Boothroyd DB; Owens DK; Hlatky MA Ann Intern Med; 2014 Feb; 160(4):221-32. PubMed ID: 24727840 [TBL] [Abstract][Full Text] [Related]
17. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. Chin CT; Roe MT; Fox KA; Prabhakaran D; Marshall DA; Petitjean H; Lokhnygina Y; Brown E; Armstrong PW; White HD; Ohman EM; Am Heart J; 2010 Jul; 160(1):16-22.e1. PubMed ID: 20598967 [TBL] [Abstract][Full Text] [Related]
18. Prasugrel versus clopidogrel: new management strategies for acute coronary syndrome. Schnapf AJ J Cardiovasc Nurs; 2013; 28(5):483-94. PubMed ID: 22990232 [TBL] [Abstract][Full Text] [Related]
19. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Beinart SC; Kolm P; Veledar E; Zhang Z; Mahoney EM; Bouin O; Gabriel S; Jackson J; Chen R; Caro J; Steinhubl S; Topol E; Weintraub WS J Am Coll Cardiol; 2005 Sep; 46(5):761-9. PubMed ID: 16139122 [TBL] [Abstract][Full Text] [Related]
20. Prasugrel (Effient) vs. clopidogrel (Plavix). Med Lett Drugs Ther; 2009 Sep; 51(1320):69-70. PubMed ID: 19738549 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]